Sign inJoin waitlistJoin the waitlist

Wen-Kai Weng

Program Co-Director · Stanford Health Care

Credentials: · · · ·

History

Stanford Health Care
Present
Stanford Multidisciplinary Cutaneous Lymphoma Clinic · Stanford Health Care
Present
Stanford Cancer Immunotherapy and Blood & Marrow Transplantation Symposium · Stanford Health Care
Present

Stanford University
1999–2001
Internal Medicine
University of Texas Health Science Center at Houston
1996–1999
Chung Shan Medical University
1984–1988

Research

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
Journal of Clinical Oncology · 2003 · First of 2 authors · 1,029 citations
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
Nature Medicine · 2021 · 534 citations
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project
Journal of Clinical Oncology · 2015 · 227 citations

David Miklos
42 papers
Sally Arai
40 papers
Robert Lowsky
38 papers
Robert Negrin
37 papers
Laura Johnston
36 papers
Judith Shizuru
33 papers
Lori Muffly
32 papers
Andrew Rezvani
31 papers
Matthew Frank
29 papers · 2 as a fellow
Everett Meyer
28 papers
Parveen Shiraz
26 papers
Surbhi Sidana
25 papers

Grants

Mechanism of Antibody Therapy in Human B Cell Lymphoma
National Cancer Institute · K08
Contact PI · $414.3K · Stanford University
2005–2009

Clinical trials

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG
Principal investigator · Completed · Phase 2
Stanford University
2009–2014
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
Principal investigator · Completed · Phase 2
Stanford University
2009–2022
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
Principal investigator · Terminated · Phase 2
Stanford University
2007–2017
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
Principal investigator · Terminated · Phase 2
Stanford University
2006–2010